Literature DB >> 27863924

Successful Use of Afatinib After Erlotinib-induced Pneumonitis in a Patient With Epidermal Growth Factor Receptor-mutant Lung Cancer.

Christopher D Jakubowski1, Andrew J Plodkowski2, Jason C Chang3, Natasha Rekhtman3, Afsheen Iqbal4, Paul K Paik5, Helena A Yu6.   

Abstract

Entities:  

Keywords:  Drug toxicity; Drug-induced pneumonitis; EGFR-mutant lung cancer; EGFR-tyrosine kinase inhibitors; Interstitial lung disease

Mesh：

Substances：

Year:  2016        PMID： 27863924      PMCID： PMC5490243          DOI： 10.1016/j.cllc.2016.10.001

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  12 in total

1.  Drug-induced pneumonitis: thin-section CT findings in 60 patients.

Authors:  Masanori Akira; Hideo Ishikawa; Satoru Yamamoto
Journal:  Radiology       Date:  2002-09       Impact factor: 11.105

2.  Successful treatment with erlotinib after gefitinib-induced severe interstitial lung disease.

Authors:  Masayuki Takeda; Isamu Okamoto; Chihiro Makimura; Masahiro Fukuoka; Kazuhiko Nakagawa
Journal:  J Thorac Oncol       Date:  2010-07       Impact factor: 15.609

3.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Authors:  Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2012-01-26       Impact factor: 41.316

4.  Erlotinib in previously treated non-small-cell lung cancer.

Authors:  Frances A Shepherd; José Rodrigues Pereira; Tudor Ciuleanu; Eng Huat Tan; Vera Hirsh; Sumitra Thongprasert; Daniel Campos; Savitree Maoleekoonpiroj; Michael Smylie; Renato Martins; Maximiliano van Kooten; Mircea Dediu; Brian Findlay; Dongsheng Tu; Dianne Johnston; Andrea Bezjak; Gary Clark; Pedro Santabárbara; Lesley Seymour
Journal:  N Engl J Med       Date:  2005-07-14       Impact factor: 91.245

5.  Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer.

Authors:  Ken Y Yoneda; David K Shelton; Laurel A Beckett; David R Gandara
Journal:  J Thorac Oncol       Date:  2007-06       Impact factor: 15.609

6.  Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series.

Authors:  Anne Bergeron; Delphine Réa; Vincent Levy; Clément Picard; Véronique Meignin; Jérome Tamburini; Heriberto Bruzzoni-Giovanelli; Fabien Calvo; Abdellatif Tazi; Philippe Rousselot
Journal:  Am J Respir Crit Care Med       Date:  2007-06-28       Impact factor: 21.405

7.  Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease.

Authors:  Tomoya Fukui; Sakiko Otani; Ryuji Hataishi; Shi-Xu Jiang; Yasuto Nishii; Satoshi Igawa; Hisashi Mitsufuji; Masaru Kubota; Masato Katagiri; Noriyuki Masuda
Journal:  Cancer Chemother Pharmacol       Date:  2009-12-25       Impact factor: 3.333

8.  AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

Authors:  Pasi A Jänne; James Chih-Hsin Yang; Dong-Wan Kim; David Planchard; Yuichiro Ohe; Suresh S Ramalingam; Myung-Ju Ahn; Sang-We Kim; Wu-Chou Su; Leora Horn; Daniel Haggstrom; Enriqueta Felip; Joo-Hang Kim; Paul Frewer; Mireille Cantarini; Kathryn H Brown; Paul A Dickinson; Serban Ghiorghiu; Malcolm Ranson
Journal:  N Engl J Med       Date:  2015-04-30       Impact factor: 91.245

9.  Drug induced interstitial lung disease.

Authors:  Martin Schwaiblmair; Werner Behr; Thomas Haeckel; Bruno Märkl; Wolfgang Foerg; Thomas Berghaus
Journal:  Open Respir Med J       Date:  2012-07-27

10.  Erlotinib achieved partial response in a non-small cell lung cancer patient with gefitinib-induced interstitial lung disease.

Authors:  Qing Tian; Liang-An Chen
Journal:  Case Rep Oncol       Date:  2011-09-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.